The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sofronov A.G.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova, Sankt-Peterburg

Spikina A.A.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova, Sankt-Peterburg

Parfenov Yu.A.

Saint Petersburg Institute of Bioregulation and Gerontologу, North-Western Branch, Russian Academy of Science

Indicators of treatment of schizophrenia in different stages of psychiatric care

Authors:

Sofronov A.G., Spikina A.A., Parfenov Yu.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2): 22‑26

DOI: 10.17116/jnevro201411411222-26

Read: 1436 times

Download PDF (RU)
Contact the author
Table of contents

INDICATORS OF TREATMENT OF SCHIZOPHRENIA IN DIFFERENT STAGES OF PSYCHIATRIC CARE
INDICATORS OF TREATMENT OF SCHIZOPHRENIA IN DIFFERENT STAGES OF PSYCHIATRIC CARE

To cite this article:

Sofronov AG, Spikina AA, Parfenov YuA. Indicators of treatment of schizophrenia in different stages of psychiatric care. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2):22‑26. (In Russ.)
https://doi.org/10.17116/jnevro201411411222-26

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
Age transformation of leading clinical diagnoses in adolescents and young people with non-suicidal self-harm. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):48-56
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Surgical mana­gement of patients with local recu­rrence of renal cancer. Prognostic factors of survival. P.A. Herzen Journal of Onco­logy. 2025;(3):20-24
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15
Abstract:

Objective. To study indicators of treatment of schizophrenia in different stages of psychiatric care, to reveal prognostic factors of the dynamics of psychopathological symptoms in treatment of schizophrenia and to estimate the risk of schizophrenia relapse. Material and methods. Three hundreds of patients, aged 18-65 years, diagnosed with schizophrenia (ICD-10) were included in data analysis. Patients were stratified into 4 groups by the type of psychiatric care: inpatients (n=68), outpatients of day hospital (n=71), outpatients of psychoneurological dispensary rehabilitation department (n=75) and outpatients supervised by psychoneurological dispensary local doctor. Treatment characteristics (use of 1st and 2nd generation antipsychotics) of these groups were compared. Results and conclusion. The positive effect of modern antipsychotics on schizophrenia course, frequency of relapses and hospitalizations was identified. The results can help in improvement of psychiatric care due to wide implementation of 2nd generation antipsychotics.

Keywords:

schizophrenia
atypical antipsychotics
prognostic factors

Authors:

Sofronov A.G.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova, Sankt-Peterburg

Spikina A.A.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova, Sankt-Peterburg

Parfenov Yu.A.

Saint Petersburg Institute of Bioregulation and Gerontologу, North-Western Branch, Russian Academy of Science

Close metadata

References:

  1. Goldner E.M., Hsu L., Waraich P., Somers J.M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002; 47: 9: 833-843.
  2. Hyde T., Goldberg T.E. et al. Frontal release signs and cognition in people with schizophrenia, their siblings and healthy controls. The British Journal of Psychiatry 2007; 191: 120-125.
  3. Üstün T.B. The global burden of mental disorders. American Journal of Public Health 1999; 89: 1315-1318.
  4. Seiku Yu.V., Khar'kova T.L., Solokhina T.A., Rotshtein V.G. Osnovnye tendentsii demograficheskogo razvitiya Rossii i dinamika chislennosti bol'nykh shizofreniei. Zhurn nevropatol i psikhiat 1998; 98: 1: 40-44.
  5. Yanichak F.D., Devis D.M., Preskorn Sh.Kh. Printsipy i praktika psikhofarmakoterapii. Kiev 1999; 725.
  6. Frith C. Consciousness and Cognition The self in action: Lessons from delusions of control 2005; 14: 752-770.
  7. Sim K., Chan Y.H., Chua T.H. et al. Physical comorbidity, insight, quality of life and global functioning in first episode schizophrenia: A 24-month, longitudinal outcome study. Schizophr Res 2006; 88: 1-3: 82-89.
  8. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatric Clinics of North America 1993; 16: 259-312.
  9. Sharma T., Harvey P. Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies (Oxford Medical Publications) 2000.
  10. Belousov Yu.B., Zyryanov S.K., Belousov D.Yu. Mul'tifaktornyi kliniko-ekonomicheskii analiz effektivnosti primeneniya sovremennykh atipichnykh antipsikhotikov u bol'nykh s shizofreniei. Kachestvennaya klinicheskaya praktika 2011; 1: 51-57.
  11. Lyubov E.B., Yastrebov V.S., Shevchenko L.S., Chapurin S.A., Churilin Yu.Yu., Bylim I.A., Gazha A.K., Doronin V.V., Kosov A.M., Petukhov Yu.L., Fadeev P.N. Ekonomicheskoe bremya shizofrenii v Rossii. Sots i klin psikhiatr 2012; 22: 3: 36-42.
  12. Omel'yanovskii V.V., Avksent'eva M.V., Ivakhnenko O.I., Khailov P.M., Tsfasman F.M., Zorin N.A. Otsenka kliniko-ekonomicheskoi effektivnosti lecheniya shizofrenii atipichnymi antipsikhotikami prolongirovannogo deistviya v in''ektsionnoi forme s uchetom priverzhennosti patsientov k terapii. Sots i klin psikhiatr 2012; 3.
  13. Sofronov A.G., Spikina A.A., Parfenov Yu.A. Dinamika naznachaemosti antipsikhotikov v Sankt Peterburge (2006-2011). Sots i klin psikhiatr 2012; 22: 4: 63-68.
  14. Sofronov A.G., Spikina A.A., Savel'ev A.P., Parfenov Yu.A. Analiz rezul'tatov podderzhivayushchei terapii shizofrenii. Obozrenie psikhiatrii i meditsinskoi psikhologii 2013; 1: 101-113.
  15. Sofronov A.G., Spikina A.A. Primenenie paliperidona pal'mitata v terapii paranoidnoi shizofrenii v ambulatornoi praktike: opisanie klinicheskogo sluchaya. Sots i klin psikhiatr 2013; 23.
  16. Efroimson V.P. Genetika oligofrenii, psikhozov, epilepsii. M: Meditsina 1978; 341.
  17. Tarify na meditsinskie uslugi, vvedennye v deistvie s 01.05.13, utverzhdennye prikazom MGFOMS ot 30.04.2013 №60.
  18. Attard A., Olofinjana O., Cornelius V., Curtis V., Taylor D. Paliperidone palmitate long-acting injection - prospective year-long follow-up of use in clinical practice. Acta Psychiatr Scad 2013.
  19. Canuso C.M., Turkoz I., Sheehan J.J., Bossie C.A. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. J Affect Dis 2010; 120: 1-3: 193-189.
  20. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 551-564.
  21. Eggert C., Bunk D. The long-term course of childhood-onset schizophrenia: a 42-year follow-up. Schizophr Bull 1997; 23: 1: 105-111.
  22. Coppola D., Lin Y., Gopal S. et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 2012; 28: 1: 26.
  23. Gopal S., Gassmann-Mayer J., Samtani M.N. et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opinion 2010; 26: 2: 377-387.
  24. Petersen, Jens: "Europäische Kommission erteilt Zulassung für XEPLION® zur Behandlung von Schizophrenie", 09. März 2011, Beerse, Belgien (feed://www.presseportal.de/rss/pm_17903.rss2)
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.